Apyx Medical Inc (APYX) Stock Analysis

AI analysis of Apyx Medical Inc (APYX)

Buy

Apyx Medical Corp appears to be a good buy right now, trading at $2.60 with a recent RSI of 56.79, indicating a balanced momentum. The forward P/E ratio is quite high at 72.46, suggesting that while the stock may be overvalued in the short term, the growth potential is significant. The stock has shown a 5.69% increase over the past five days, indicating positive short-term momentum. Furthermore, Maxim Group's buy rating reflects confidence in the company's innovative technology and growth potential, particularly as they raised their revenue guidance for 2026 to between $59 million and $60 million. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

Valuation Metrics

The current forward P/E ratio for Apyx Medical Inc (APYX) is 72.46, compared to its 5-year average forward P/E of 5.82.

Forward P/E

Strongly Overvalued

5Y Average P/E

5.82

Current P/E

72.46

Overvalued

36.80

Undervalued

-25.16

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-9.40

Current EV/EBITDA

-15.53

Overvalued

30.40

Undervalued

-49.21

Forward P/S

Fair

5Y Average P/S

2.49

Current P/S

1.65

Overvalued

4.41

Undervalued

0.56

Alphio AI Price Scenarios for APYX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%APYX

$1.80

Scenario price

B

Base

Base · 50%APYX

$1.74

Scenario price

B

Bear

Bear · 25%APYX

$1.70

Scenario price

Whales holding APYX

N

Nantahala Capital Management, LLC

+ HoldingAPYX

+10.21%

3M Return

APYX FAQ — answered by Alphio AI

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Apyx Medical Corp appears to be a good buy right now, trading at $2.60 with a recent RSI of 56.79, indicating a balanced momentum. The forward P/E ratio is quite high at 72.46, suggesting that while the stock may be overvalued in the short term, the growth potential is significant. The stock has shown a 5.69% increase over the past five days, indicating positive short-term momentum. Furthermore, Maxim Group's buy rating reflects confidence in the company's innovative technology and growth potential, particularly as they raised their revenue guidance for 2026 to between $59 million and $60 million. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.